Experimental vaccine aims to stop melanoma recurrence in its tracks
NCT ID NCT01898039
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a vaccine made from modified melanoma cells in patients who had their tumors removed but are at high risk of recurrence. The vaccine is designed to train the immune system to recognize and attack any remaining cancer cells. Up to 50 participants will receive multiple injections over several months, with researchers monitoring safety and immune response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
A2/4-1BBL melanoma vaccine (M20/A2B cells)
What this could lead to
If successful, this vaccine could help prevent melanoma from coming back in patients at high risk of recurrence after tumor removal.
What could go wrong
This is an early phase I/II trial with only 50 participants, so results may not apply to all patients. The vaccine may cause side effects or fail to stimulate a strong enough immune response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sharett Institute of Oncology, Hadassah Medical Organization
RECRUITINGJerusalem, 91120, Israel
Contact Email: •••••@•••••